Howard Cuckle, are available online and in the August issue of Obstetrics and Gynecology. The results of this study, entitled " SNP-based Non-invasive Prenatal Screening in a High-risk and Low-risk Cohort,” by lead authors Dr. Natera is helping to enable change through its leadership in scientific research, designing and conducting studies to demonstrate efficacy and clinical utility in the general population. This recommendation for testing only in the high-risk population was largely due to a lack of sufficient data about test performance in lower risk pregnancies, which this study from Natera is meant to address. NIPT, based on analyzing cell-free fetal DNA circulating in maternal blood, was initially recommended for use in the high-risk pregnant population - typically pregnant women 35 years of age or older or pregnant women who carry some other known risk for a fetal chromosomal disorder. “We expect that this study, when combined with the growing body of evidence in the scientific literature, will give the medical community added comfort that Panorama works equally well in all pregnant women and would reduce the number of unwanted invasive procedures that result from other screening methods.” "The results of this study reinforce the high accuracy and reliability of Panorama’s screening technology, and Natera’s focus on patient safety as the number one priority,” said Susan Gross, M.D., chief medical officer for Natera. This false positive rate corresponds to a specificity of greater than 99.9%, which the authors found to be a statistically significant performance improvement over quantitative NIPT methods, made possible by Panorama’s unique ability to differentiate between maternal and fetal DNA. This study of more than 1,000 pregnant patients, half of whom were low risk, showed that Panorama’s false positive rate is less than 0.1% when screening for trisomies 21, 18, and 13. This is the first major published study of Panorama that provides compelling scientific evidence for testing in the general population. Natera, Inc., a leader in non-invasive genetic testing, today announced a study published in the August issue of Obstetrics and Gynecology, which demonstrates that the Panorama non-invasive prenatal test (NIPT) performs consistently well in all pregnant women, regardless of their prior risk level.
Schedule Blood Draw (Existing Patients).Order Tests and Track Status on NateraConnect.Schedule Session with Patient Coordinator.NEVA for Empower – Natera’s Educational Virtual Assistant.Vasistera – Limited Noninvasive Prenatal Testing (NIPT).Panorama – Noninvasive Prenatal Testing (NIPT).Prospera Kidney – Transplant Assessment.Signatera for Colorectal Cancer Patients.Signatera – Residual Disease Test (MRD).
0 kommentar(er)
